An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels

Journal of Controlled Release

Volumn 158, Issue 3, 2012, Pages 379-385

  Zahedi, Payam ^a   Stewart, James ^b,c   De Souza, Raquel ^a   Piquette Miller, Micheline ^a   Allen, Christine ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Docetaxel; Intraperitoneal sustained chemotherapy; Intratumoral distribution; Ovarian cancer; Tumor penetration

Indexed keywords

DOCETAXEL; INTRAPERITONEAL; INTRATUMORAL DISTRIBUTION; OVARIAN CANCER; TUMOR PENETRATION;

BIODEGRADABLE POLYMERS; BLOOD VESSELS; CELL DEATH; CHEMOTHERAPY; CORE LEVELS; DISEASES; DRUG PRODUCTS; MAMMALS; PHARMACOKINETICS;

TUMORS;

CASPASE 3; DOCETAXEL; POLYMER; POLYMER LIPID BIODEGRADABLE DEPOT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES FLUID; CANCER CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG PERITONEAL FLUID LEVEL; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUSTAINED DRUG RELEASE; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C57BL; MICE, SCID; OVARIAN NEOPLASMS; PERITONEAL CAVITY; TAXOIDS; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859258741     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.11.025     Document Type: Article

References (54)

1. K.R. Cho, and I.M. Shih Ovarian Cancer Annu. Rev. Pathol. Mech. Dis. 4 2009 287 313
2. W.P. Ceelen, and M.F. Flessner Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence Nat. Rev. Clin. Oncol. 7 2010 108 115
3. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Williams, J.A. Young, E.W. Franklin, D.L. ClarkePearson, V.K. Malviya, B. DuBeshter, M.D. Adelson, and W.J. Hoskins Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N. Engl. J. Med. 335 1996 1950 1955 (Pubitemid 26428219)
4. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, S. Lele, L.J. Copeland, J.L. Walker, and R.A. Burger Intraperitoneal cisplatin and paclitaxel in ovarian cancer N. Engl. J. Med. 354 2006 34 43 (Pubitemid 43048949)
5. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, L.F. Carson, S. Wadler, and J. Sickel Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J. Clin. Oncol. 19 2001 1001 1007 (Pubitemid 32176274)
6. J.L. Lesnock, S.D. Richard, K.K. Zorn, T.C. Krivak, S. Beriwal, P. Sukumvanich, W.C. McBee, J.L. Kelley, and R.P. Edwards Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications Gynecol. Oncol. 116 2010 345 350
7. K. Hirano, and C.A. Hunt Lymphatic Transport of Liposome-Encapsulated Agents - Effects of Liposome Size Following Intraperitoneal Administration J. Pharm. Sci. 74 1985 915 921 (Pubitemid 15014130)
8. D.S. Kohane, J.Y. Tse, Y. Yeo, R. Padera, M. Shubina, and R. Langer Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum J. Biomed. Mater. Res. A 77A 2006 351 361 (Pubitemid 47233537)
9. M. Tsai, Z. Lu, J. Wang, T.K. Yeh, M.G. Wientjes, and J.L.S. Au Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel Pharm. Res. 24 2007 1691 1701 (Pubitemid 47206619)
10. S. Natsugoe, K. Tokuda, M. Shimada, T. Kumanohoso, M. Baba, S. Takao, M. Tabata, K. Nakamura, H. Yoshizawa, and T. Aikou Morphology of the designed biodegradable cisplatin microsphere Anticancer Res. 19 1999 5163 5167 (Pubitemid 30103341)
11. D.K. Armstrong, G.F. Fleming, M. Markman, and H.H. Bailey A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer®) in recurrent ovarian cancer: A Gynecologic Oncology Group study Gynecol. Oncol. 103 2006 391 396 (Pubitemid 44604492)
12. J. Grant, M. Blicker, M. Piquette-Miller, and C. Allen Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel J. Pharm. Sci. 94 2005 1512 1527 (Pubitemid 41168681)
13. E.A. Ho, V. Vassileva, C. Allen, and M. Piquette-Miller In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel J. Control. Release 104 2005 181 191 (Pubitemid 40615245)
14. P. Lim Soo, J. Cho, J. Grant, E. Ho, M. Piquette-Miller, and C. Allen Drug release mechanism of paclitaxel from a chitosan-lipid implant system: Effect of swelling, degradation and morphology Eur. J. Pharm. Biopharm. 69 2008 149 157
15. V. Vassileva, J. Grant, R. De Souza, C. Allen, and M. Piquette-Miller Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model Cancer Chemother. Pharmacol. 60 2007 907 914 (Pubitemid 47389398)
16. V. Vassileva, E.H. Moriyama, R. De Souza, J. Grant, C.J. Allen, B.C. Wilson, and M. Piquette-Miller Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging Br. J. Cancer 99 2008 2037 2043
17. E. de Bree, P.A. Theodoropoulos, H. Rosing, J. Michalakis, J. Romanos, J.H. Beijnen, and D.D. Tsiftsis Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside Eur. J. Surg. Oncol. 32 2006 471 482 (Pubitemid 44321352)
18. H. Hernandez-Vargas, J. Palacios, and G. Moreno-Bueno Telling cells how to die - Docetaxel therapy in cancer cell lines Cell Cycle 6 2007 780 783 (Pubitemid 46572613)
19. S.N. Gardner A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs Cancer Res. 60 2000 1417 1425 (Pubitemid 30152016)
20. P. Zahedi, R. De Souza, M. Piquette-Miller, and C. Allen Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity Int. J. Pharm. 377 2009 76 84
21. R. De Souza, P. Zahedi, C.J. Allen, and M. Piquette-Miller Biocompatibility of injectable chitosan-phospholipid implant systems Biomaterials 30 2009 3818 3824
22. R. De Souza, P. Zahedi, E.H. Moriyama, C.J. Allen, B.C. Wilson, and M. Piquette-Miller Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer Mol. Cancer Ther. 9 2010 1820 1830
23. R. De Souza, P. Zahedi, R.M. Badame, C.J. Allen, and M. Piquette-Miller Chemotherapy dosing schedule influences drug resistance development in ovarian cancer Mol. Cancer Ther. 10 2011 1289 1299
24. S.J. Dawson, R.J. Hicks, V. Johnston, D. Allen, T. Jobling, M. Quinn, and D. Rischin Intraperitoneal distribution imaging in ovarian cancer patients Intern. Med. J. 41 2011 167 171
25. M. Deforni, A. Boneu, P. Otal, P. Martel, R. Shubinski, R. Bugat, and H. Lucot Anatomic Changes in the Abdominal-Cavity during Intraperitoneal Chemotherapy - Prospective-Study Using Scintigraphic Peritoneography Bull. Cancer 80 1993 345 350 (Pubitemid 23138504)
26. F.M. Muggia, E. Lepoidevin, S. Jeffers, C. Russell, W. Boswell, C.P. Morrow, J. Curtin, and J. Schlaerth Intraperitoneal Therapy for Ovarian-Cancer - Analysis of Fluid Distribution by Computerized-Tomography Ann. Oncol. 3 1992 149 154
27. P. Zahedi, R. De Souza, M. Piquette-Miller, and C. Allen Docetaxel distribution following intraperitoneal administration in mice J. Pharm. Pharm. Sci. 14 2011 90 99
28. J. Greenaway, R. Moorehead, P. Shaw, and J. Petrik Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer Gynecol. Oncol. 108 2008 385 394 (Pubitemid 351174296)
29. J. Cho, J. Grant, M. Piquette-Miller, and C. Allen Synthesis and physicochemical and dynamic mechanical properties of a water-soluble chitosan derivative as a biomaterial Biomacromolecules 7 2006 2845 2855 (Pubitemid 44615269)
30. O. Tredan, C.M. Galmarini, K. Patel, and I.F. Tannock Drug resistance and the solid tumor microenvironment J. Natl. Cancer Inst. 99 2007 1441 1454
31. Y. Kamijo, C. Ito, M. Nomura, Y. Sai, and K. Miyamoto Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats Cancer Lett. 287 2010 182 186
32. F. Mohamed, O.A. Stuart, and P.H. Sugarbaker Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions J. Surg. Res. 113 2003 114 120 (Pubitemid 36999800)
33. K. Yokogawa, M.J. Jin, N. Furui, M. Yamazaki, H. Yoshihara, M. Nomura, H. Furukawa, J. Ishizaki, S. Fushida, K. Miwa, and K. Miyamoto Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles J. Pharm. Pharmacol. 56 2004 629 634 (Pubitemid 38607654)
34. E. de Bree, H. Rosing, J.H. Beijnen, J. Romanos, J. Michalakis, V. Georgoulias, and D.D. Tsiftsis Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer Anticancer Drugs 14 2003 103 110 (Pubitemid 36269748)
35. R.J. Morgan, J.H. Doroshow, T. Synold, D. Lim, S. Shibata, K. Margolin, R. Schwarz, L. Leong, G. Somlo, P. Twardowski, Y. Yen, W. Chow, P. Lin, B. Paz, D. Chu, P. Frankel, and S. Stalter Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics Clin. Cancer Res. 9 2003 5896 5901 (Pubitemid 38018073)
36. S.A. Cannistra Cancer of the ovary N. Engl. J. Med. 351 2004 2519 2529
37. T.J. Shaw, M.K. Senterman, K. Dawson, C.A. Crane, and B.C. Vanderhyden Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer Mol. Ther. 10 2004 1032 1042 (Pubitemid 39625247)
38. G. Becker, D. Galandi, and H.E. Blum Malignant ascites: Systematic review and guideline for treatment Eur. J. Cancer 42 2006 589 597 (Pubitemid 43343680)
39. S.B. Decruze, R. Macdonald, G. Smith, and J.J. Herod Paracentesis in Ovarian Cancer: A Study of the Physiology during Free Drainage of Ascites J. Palliat. Med. 13 2010 251 254
40. M.F. Flessner The transport barrier in intraperitoneal therapy Am. J. Physiol. Renal Physiol. 288 2005 F433 F442
41. K. Van der Speeten, O.A. Stuart, and P.H. Sugarbaker Pharmacokinetics and Pharmacodynamics of Perioperative Cancer Chemotherapy in Peritoneal Surface Malignancy Cancer J. 15 2009 216 224
42. P. Marchettini, O.A. Stuart, F. Mohamed, D. Yoo, and P.H. Sugarbaker Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model Cancer Chemother. Pharmacol. 49 2002 499 503 (Pubitemid 34671286)
43. Z. Lu, J. Wang, M.G. Wientjes, and J.L.S. Au Intraperitoneal therapy for peritoneal cancer Future Oncol. 6 2010 1625 1641
44. R.A. Adam, and Y.G. Adam Malignant ascites: Past, present, and future J. Am. Coll. Surg. 198 2004 999 1011 (Pubitemid 38759851)
45. A.I. Minchinton, and I.F. Tannock Drug penetration in solid tumours Nat. Rev. Cancer 6 2006 583 592 (Pubitemid 44140857)
46. C. Li, R.A. Newman, Q.P. Wu, S. Ke, W. Chen, T. Hutto, Z.X. Kan, M.D. Brannan, C. Charnsangavej, and S. Wallace Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor Cancer Chemother. Pharmacol. 46 2000 416 422
47. A.H. Kyle, L.A. Huxham, D.M. Yeoman, and A.I. Minchinton Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors Clin. Cancer Res. 13 2007 2804 2810 (Pubitemid 46788050)
48. H.J. Kuh, S.H. Jang, M.G. Wientjes, J.R. Weaver, and J.L.S. Au Determinants of paclitaxel penetration and accumulation in human solid tumor J. Pharmacol. Exp. Ther. 290 1999 871 880 (Pubitemid 29344588)
49. S.H. Jang, M.G. Wientjes, and J.L.S. Au Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: Effect of treatment schedule J. Pharmacol. Exp. Ther. 296 2001 1035 1042 (Pubitemid 32187379)
50. K.M. Nicholson, M.C. Bibby, and R.M. Phillips Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids Eur. J. Cancer 33 1997 1291 1298 (Pubitemid 27359651)
51. I.F. Tannock, C.M. Lee, J.K. Tunggal, D.S.M. Cowan, and M.J. Egorin Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy Clin. Cancer Res. 8 2002 878 884 (Pubitemid 34742121)
52. I.F. Tannock, R. Grantab, and S. Sivananthan The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells Cancer Res. 66 2006 1033 1039 (Pubitemid 43165971)
53. L. Solorio, R.B. Patel, H. Wu, T. Krupka, and A.A. Exner Advances in image-guided intratumoral drug delivery techniques Ther. Deliv. 1 2011 307 322
54. G.M. van Dam, G. Themelis, L.M.A. Crane, N.J. Harlaar, R.G. Pleijhuis, W. Kelder, A. Sarantopoulos, J.S. de Jong, H.J.G. Arts, A.G.J. van der Zee, J. Bart, P.S. Low, and V. Ntziachristos Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results Nat. Med. 17 2011 1315 1319